Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa
Following Positive R&D Milestones
The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.
